drugset

drugset / Trial / NCT00677872

An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

NCT00677872 ↗

Phase 2 Terminated 40 enrolled Epix Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

A 3-month open label study to evaluate the safety and efficacy of PRX-08066 in patients with pulmonary hypertension and COPD.

Timeline

Start: 2008-05
Primary completion: 2008-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PRX-08066	Small molecule	—	—

Indications